Cipla USA Inc. the wholly owned subsidiary of Cipla Limited (500087,CIPLA) announced that it has received final approval from U.S. FDA for Abbreviated New Drug Application or ANDA for Nintedanib Capsules, 100 mg and 150 mg, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company is set to launch the product on an immediate basis, and it will be available through appropriate pharmacy distribution channels, including specialty distribution. Cipla's Nintedanib Capsules are the generic therapeutic equivalent of Ofev, marketed by Boehringer Ingelheim.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.